Research grant to understand and treat long-term side effects of cancer therapy through mechanistic and clinical studies supporting therapeutic interventions.
Funder: National Institutes of Health
Due Dates: February 5, 2027 (New) | March 5, 2027 (Resubmission) | June 5, 2027 (New) | July 5, 2027 (Resubmission) | October 5, 2027 (New) | November 5, 2027 (Resubmission) | January 7, 2028 (Closing date)
Funding Amounts: No budget limit; requests must reflect project needs; up to 5 years; no cost sharing required
Summary: Supports mechanistic, translational, and clinical research to characterize, prevent, or reduce chronic and delayed adverse effects of cancer therapies.
Key Information: Only new and resubmission applications are accepted; clinical trials are optional.
The National Cancer Institute (NCI), part of NIH, supports R01 research addressing cancer therapy-induced adverse effects that persist as chronic comorbidities or emerge after treatment. Projects may involve basic science, translational research, or clinical studies in adult or pediatric populations. The goal is to connect mechanistic understanding with clinical characterization and therapeutic approaches that prevent or minimize long-term sequelae.
Research interests include longitudinal phenotyping, objective measures of toxicity, validation of biomarkers and other clinical endpoints, risk factors, and prevention or mitigation strategies. Projects linking mechanisms with clinical phenotypes receive priority. Clinical–basic science collaborations, understudied and underserved cancer populations, and emerging treatments are encouraged. Preclinical studies are strongly encouraged to validate findings in human tissue or human-derived cells.